Low-temperature steel flux-cored wire
A technology of flux-cored welding wire and low-temperature steel, which is applied in the direction of welding medium, welding equipment, welding/cutting medium/material, etc., can solve the problems of poor welding process performance, poor arc stability, and high cost, and achieve low-temperature impact toughness and low-temperature resistance Good crack resistance, excellent low temperature impact toughness, high welding efficiency
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0013] The preparation method of the present invention adopts prior art, is manufactured with following process:
[0014] 1. Raw materials for preparing the drug core: rutile, wollastonite, silicon-manganese alloy, iron powder, nickel powder, cryolite, feldspar, ferro-titanium, ferro-boron, medium-carbon ferromanganese, magnesia, quartz and fluorite. Requirements TiO in rutile 2 The content is 96%; CaSiO in wollastonite 3 The content of Si is 67%; Si 22% in silicon-manganese alloy, Mn 78%; Fe content in iron powder is 98%; Ni content in nickel powder is 99%; Na in cryolite 3 AlF 6 The content is 98%; SiO in feldspar 2 68%, Al 2 o 3 18%; Ti 21% in ferro-titanium; B 21% in ferro-boron; Mn 80% in medium-carbon ferromanganese; MgO content in magnesia is 98%; SiO in quartz 2 The content is 98%; CaF in fluorite 2 The content is 98%. And crush all the above raw materials to the powder that can pass through a 60 mesh sieve;
[0015] 2. prepare drug core of the present inventi...
Embodiment 2
[0023] Manufactured by:
[0024] 1. Raw materials for preparing the drug core: rutile, wollastonite, silicon-manganese alloy, iron powder, nickel powder, cryolite, feldspar, ferro-titanium, ferro-boron, medium-carbon ferromanganese, magnesia, quartz and fluorite. Requirements TiO in rutile 2 The content is 96%; CaSiO in wollastonite 3 The content of Si is 67%; Si 22% in silicon-manganese alloy, Mn 78%; Fe content in iron powder is 98%; Ni content in nickel powder is 99%; Na in cryolite 3 AlF 6 The content is 98%; SiO in feldspar 2 68%, Al 2 o 3 18%; Ti 21% in ferro-titanium; B 21% in ferro-boron; Mn 80% in medium-carbon ferromanganese; MgO content in magnesia is 98%; SiO in quartz 2 The content is 98%; CaF in fluorite 2 The content is 98%. And crush all the above raw materials to the powder that can pass through a 60 mesh sieve;
[0025] 2. prepare drug core of the present invention by the weight percentage of following raw material:
[0026] 33% rutile; 2% wollaston...
Embodiment 3
[0033] Manufactured by:
[0034] 1. Raw materials for preparing the drug core: rutile, wollastonite, silicon-manganese alloy, iron powder, nickel powder, cryolite, feldspar, ferro-titanium, ferro-boron, medium-carbon ferromanganese, magnesia, quartz and fluorite. TiO in rutile 2 The content is 96%; CaSiO in wollastonite 3 The content of Si is 67%; Si 22% in silicon-manganese alloy, Mn 78%; Fe content in iron powder is 98%; Ni content in nickel powder is 99%; Na in cryolite 3 AlF 6 The content is 98%; SiO in feldspar 2 68%, Al 2 o 3 18%; Ti 21% in ferro-titanium; B 21% in ferro-boron; Mn 80% in medium-carbon ferromanganese; MgO content in magnesia is 98%; SiO in quartz 2 The content is 98%; CaF in fluorite 2 The content is 98%. And crush all the above raw materials to the powder that can pass through a 60 mesh sieve;
[0035] 2. prepare drug core of the present invention by the weight percentage of following raw material:
[0036] 30% rutile; 3% wollastonite; 16% sili...
PUM
| Property | Measurement | Unit |
|---|---|---|
| particle size | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More